Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.22 Insider Own14.49% Shs Outstand15.00M Perf Week10.13%
Market Cap102.65M Forward P/E- EPS next Y-2.76 Insider Trans0.00% Shs Float13.02M Perf Month23.90%
Income-101.03M PEG- EPS next Q-1.04 Inst Own24.40% Short Float2.41% Perf Quarter48.46%
Sales4.26M P/S24.10 EPS this Y49.23% Inst Trans-24.80% Short Ratio0.47 Perf Half Y67.83%
Book/sh2.88 P/B2.34 EPS next Y28.32% ROA-78.11% Short Interest0.31M Perf Year-3.78%
Cash/sh3.44 P/C1.96 EPS next 5Y- ROE-112.36% 52W Range2.23 - 8.95 Perf YTD7.84%
Dividend Est.- P/FCF- EPS past 5Y-82.40% ROI-187.35% 52W High-24.69% Beta2.16
Dividend TTM- Quick Ratio3.06 Sales past 5Y-4.04% Gross Margin- 52W Low201.57% ATR (14)0.75
Dividend Ex-Date- Current Ratio3.06 EPS Y/Y TTM-350.09% Oper. Margin-2525.54% RSI (14)60.77 Volatility13.86% 14.27%
Employees78 Debt/Eq0.40 Sales Y/Y TTM-89.07% Profit Margin-2371.79% Recom1.29 Target Price18.16
Option/ShortYes / Yes LT Debt/Eq0.23 EPS Q/Q-498.56% Payout- Rel Volume0.37 Prev Close7.10
Sales Surprise-63.54% EPS Surprise17.95% Sales Q/Q-96.52% EarningsJun 12 BMO Avg Volume672.32K Price6.74
SMA2019.80% SMA5022.56% SMA20032.09% Trades Volume248,441 Change-5.07%
Date Action Analyst Rating Change Price Target Change
Dec-12-22Initiated H.C. Wainwright Buy $6
Oct-10-22Downgrade Stifel Buy → Hold $9 → $2
Aug-18-22Resumed Wells Fargo Overweight
Mar-31-22Initiated Piper Sandler Overweight $7
Feb-23-22Initiated Cantor Fitzgerald Overweight $12
Oct-21-21Initiated Truist Buy $10
Sep-30-21Initiated Stifel Buy $12
Mar-31-21Initiated Credit Suisse Outperform $15
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Jun-14-24 05:34PM
Jun-13-24 08:02AM
Jun-12-24 10:52AM
06:30AM Loading…
Jun-05-24 06:30AM
Jun-04-24 11:32AM
Jun-03-24 04:13PM
Jun-01-24 01:02PM
May-29-24 06:30AM
May-28-24 06:30AM
May-23-24 05:05PM
May-17-24 03:55PM
10:05AM Loading…
May-14-24 10:05AM
Apr-24-24 09:55AM
Apr-17-24 09:55AM
Apr-04-24 09:55AM
Apr-01-24 11:38AM
Mar-28-24 06:30AM
Mar-21-24 06:30AM
Mar-14-24 12:00PM
Mar-06-24 03:36PM
Jan-08-24 04:05PM
Jan-03-24 06:30AM
Dec-19-23 09:08AM
06:02AM Loading…
Dec-11-23 06:02AM
Dec-04-23 06:30AM
Nov-20-23 08:51AM
Nov-14-23 06:38AM
Nov-09-23 06:30AM
Nov-07-23 06:30AM
Nov-03-23 12:05PM
Nov-02-23 09:05AM
Nov-01-23 06:30AM
Oct-31-23 07:12PM
Oct-25-23 09:35AM
Oct-04-23 06:30AM
Sep-27-23 09:05AM
Sep-21-23 06:30AM
Sep-12-23 06:30AM
Sep-07-23 06:30AM
Aug-23-23 12:11PM
Aug-22-23 05:00AM
Aug-10-23 07:50AM
Aug-09-23 06:02AM
Aug-04-23 04:51PM
Aug-03-23 06:30AM
Jul-31-23 05:05PM
Jun-22-23 06:30AM
Jun-09-23 05:59PM
Jun-06-23 07:51AM
Jun-03-23 09:00AM
May-30-23 06:30AM
May-25-23 05:00PM
May-23-23 07:45AM
May-22-23 06:30AM
May-16-23 06:30AM
May-11-23 10:05AM
May-05-23 06:14AM
Apr-26-23 10:00AM
Apr-17-23 04:05PM
Apr-16-23 03:00PM
Apr-06-23 04:05PM
Mar-30-23 08:19AM
Mar-29-23 06:30AM
Mar-27-23 06:21AM
Mar-23-23 07:45AM
Mar-16-23 06:30AM
Mar-14-23 04:30PM
Mar-09-23 05:00AM
Feb-22-23 06:30AM
Feb-21-23 05:00AM
Feb-08-23 06:30AM
Jan-09-23 06:30AM
Dec-28-22 06:41AM
Dec-22-22 06:30AM
Dec-16-22 09:35AM
Dec-12-22 01:01PM
Dec-10-22 03:00PM
Dec-01-22 04:05PM
Nov-17-22 04:01PM
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.